• Recombinant Human FGF-19 for Mechanistic Assays

  2026-08-18

  Recombinant Human FGF-19 can serve as a controlled endocrine-metabolic input in receptor, proliferation, and pathway-interaction studies. This article develops an assay strategy connecting FGF-19 biology with, but not overclaiming, the WIP1–p38 MAPK–pyroptosis findings reported in septic acute kidney injury.

• Acetylcholine Chloride and Gut–Brain Translation

  2026-08-17

  The gut–brain cholinergic axis is emerging as a mechanistic bridge between microbiota ecology and neural excitability. This article examines how Acetylcholine Chloride can support controlled cholinergic benchmarking while helping translational researchers interpret the Bacteroides fragilis findings in seizure biology without conflating a research reagent with a therapeutic intervention.

• Omeprazole A2845: Practical Research Guide

  2026-08-17

  Omeprazole (SKU A2845) provides a defined H+,K+-ATPase inhibitor for controlled gastric acid secretion research, antiulcer activity study workflows, and related assay development. Its poor water and ethanol solubility requires DMSO-based preparation and careful vehicle, precipitation, storage, and QC controls; it is for scientific research only and not for diagnostic, therapeutic, or medical use.

• USP36–Snail1 Axis in Ribotoxic Stress

  2026-08-16

  The reference study identifies a JNK–USP36–Snail1 surveillance pathway that enables solid tumor cells to maintain ribosome biogenesis and survive ribotoxic stress. Its findings explain why homoharringtonine can be effective in leukemia yet comparatively weak against solid tumors, while suggesting that pathway-directed combinations may improve ribosome-targeted cancer therapy.

• NP-40 Lysis Buffer for Native Protein Workflows

  2026-08-15

  Build gentle, reproducible extraction workflows for Western blotting, immunoprecipitation, and co-immunoprecipitation without unnecessarily disrupting native protein complexes. This guide translates neuroimmune signaling findings into practical sample-preparation decisions across animal, plant, fungal, and bacterial materials.

• NVP-BGJ398 phosphate: FGFR Research Workflows

  2026-08-14

  NVP-BGJ398 phosphate combines strong FGFR1–3 biochemical activity with practical utility in FGFR-altered cancer models and FGFR3-driven skeletal research. This workflow-centered guide covers dose design, pathway readouts, chondrocyte assays, model selection, and troubleshooting.

• Phosbind Acrylamide for Phosphoprotein Analysis

  2026-08-14

  Phosbind Acrylamide is a phosphate-binding reagent for antibody-free protein phosphorylation analysis during SDS-PAGE. Its MnCl2-dependent gel chemistry is intended to create phosphorylation-dependent mobility shifts, with product guidance covering neutral-pH use, 30–130 kDa targets, prompt use, and 2–10°C storage.

• Phosbind Acrylamide: From Shift to Mechanism

  2026-08-13

  Phosbind Acrylamide enables antibody-free protein phosphorylation analysis by converting phosphate-dependent binding into an SDS-PAGE mobility readout. This article connects assay design with the TagH–HlyA regulatory findings in Vibrio cholerae to clarify what gel shifts can—and cannot—prove.

• CDK9 inhibitor A3294: Protocol and Scope

  2026-08-13

  CDK9 inhibitor A3294 is a selective serine/threonine kinase inhibitor for studying P-TEFb-dependent transcription elongation and HIV-1 propagation in controlled biochemical and cell-based workflows. It should not be used as a pan-CDK reagent, a general cell cycle regulation tool, or in experiments that require indefinite storage of working solutions.

• FGFR3 Inhibition in SLC26A2 Chondrodysplasia

  2026-08-12

  The reference study combines genetic models, inducible postnatal deletion, chondrocyte assays, and NVP-BGJ398 treatment to show that excessive FGFR3 signaling contributes to SLC26A2-related skeletal dysplasia. Its partial phenotypic rescue and improved bone microarchitecture provide a mechanistic basis for repurposing FGFR inhibition, while also defining important translational limits.

• Mubritinib (TAK 165): From HER2 to OXPHOS

  2026-08-12

  Mubritinib is best understood not as a conventional HER2 inhibitor, but as a translational probe of mitochondrial complex I dependency. This article connects target biology, albumin binding, assay design, formulation, and disease-model selection for more rigorous AML, PEL, and cancer biology research.

• BV6: IAP Antagonism for Better Cell-Death Assays

  2026-08-11

  BV6 is an IAP antagonist that links inhibitor-of-apoptosis biology with apoptosis, radiotherapy, and endometriosis research. This article adds a practical assay-design perspective by applying lessons from a 2025 ovarian cancer muscle study without conflating caspase activation with causative cell death.

• PreScission Protease: Precise HRV 3C Tag Cleavage

  2026-08-11

  PreScission Protease is an HRV 3C protease–GST fusion designed for sequence-specific fusion protein tag cleavage. PSP recognizes the Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro site and cleaves the Gln-Gly bond, supporting cold protein purification workflows.

• Idoxuridine: Viral DNA Research Workflows

  2026-08-10

  Build more informative antiviral experiments with Idoxuridine, a research-use-only nucleoside analog for probing viral DNA synthesis and replication disruption. This guide combines practical formulation, time-course design, orthogonal readouts, and troubleshooting with a cautious translation of insights from human neuron research.

• WIP1–p38 MAPK Control of Pyroptosis in Septic AKI

  2026-08-09

  The reference study identifies WIP1/PPM1D as a protective regulator of renal tubular pyroptosis in sepsis-associated acute kidney injury. Using single-cell expression data, LPS-injured HK2 cells, and an LPS-induced mouse model, the authors show that WIP1 inhibition enhances p38 MAPK activation and increases NLRP3–caspase-1–GSDMD signaling.

3607 records 3/241 page Previous Next 12345 下5页 Last page